Huaren Pharmaceutical Co Ltd
SZSE:300110
Intrinsic Value
Huaren Pharmaceutical Co., Ltd. engages in development, manufacture, and sale of non polyvinyl chloride and non-PVC large capacity preparations. [ Read More ]
The intrinsic value of one
Huaren Pharmaceutical Co Ltd
stock under the Base Case scenario is
3.56
CNY.
Compared to the current market price of 3.23 CNY,
Huaren Pharmaceutical Co Ltd
is
Undervalued by 9%.
Huaren Pharmaceutical Co Ltd's market capitalization is 3.8B CNY.
Huaren Pharmaceutical Co Ltd stock price is 3.23 CNY.
Huaren Pharmaceutical Co Ltd stock price (3.23 CNY) is 9% less than its Intrinsic Value (3.56 CNY).
Huaren Pharmaceutical Co Ltd stock (2.01 CNY) is 38% less than its price (3.23 CNY). Open DCF Valuation
Huaren Pharmaceutical Co Ltd stock price (3.23 CNY) is 37% less than its Relative Value (5.1 CNY). Open Relative Valuation
Huaren Pharmaceutical Co Ltd has upside potential of 372% compared to the average analyst price target.
Open Wall St Estimates
Huaren Pharmaceutical Co Ltd's Revenue has grown by 0% over the past 12 months.
Huaren Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 5% to 5%.
Huaren Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Huaren Pharmaceutical Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 5% to 8%.
Huaren Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
Huaren Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Huaren Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
Huaren Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 7%. The company is efficient at transforming stockholders' equity into net income.
Huaren Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Huaren Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
Huaren Pharmaceutical Co Ltd's Altman Z-Score is equal to 2.19.
Huaren Pharmaceutical Co Ltd's short-term assets (3B CNY) exceed its short-term liabilties (2B CNY).
Huaren Pharmaceutical Co Ltd's Revenue has been falling by 13% per year for the last 3 years.
Huaren Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Huaren Pharmaceutical Co Ltd's long-term assets (5B CNY) exceed its long-term liabilties (2B CNY).
Huaren Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.54.
Huaren Pharmaceutical Co Ltd has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (232m CNY).
Valuation Backtest
Huaren Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Huaren Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Huaren Pharmaceutical Co Ltd
Balance Sheet Decomposition
Huaren Pharmaceutical Co Ltd
| Current Assets | 2.8B |
| Cash & Short-Term Investments | 231.9m |
| Receivables | 2.2B |
| Other Current Assets | 373.4m |
| Non-Current Assets | 2.4B |
| Long-Term Investments | 25.4m |
| PP&E | 1.1B |
| Intangibles | 1.2B |
| Other Non-Current Assets | 61.4m |
| Current Liabilities | 1.5B |
| Accounts Payable | 142.3m |
| Accrued Liabilities | 198.3m |
| Short-Term Debt | 628.6m |
| Other Current Liabilities | 547.1m |
| Non-Current Liabilities | 955.3m |
| Long-Term Debt | 836.6m |
| Other Non-Current Liabilities | 118.8m |
Earnings Waterfall
Huaren Pharmaceutical Co Ltd
|
Revenue
|
1.6B
CNY
|
|
Cost of Revenue
|
-961.6m
CNY
|
|
Gross Profit
|
678.1m
CNY
|
|
Operating Expenses
|
-376.5m
CNY
|
|
Operating Income
|
301.7m
CNY
|
|
Other Expenses
|
-103.9m
CNY
|
|
Net Income
|
197.8m
CNY
|
Free Cash Flow Analysis
Huaren Pharmaceutical Co Ltd
| CNY | |
| Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Huaren Pharmaceutical Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Huaren Pharmaceutical Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Huaren Pharmaceutical Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Huaren Pharmaceutical Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Huaren Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Huaren Pharmaceutical Co Ltd
is 15.25 CNY
.
Shareholder Return
Price
Huaren Pharmaceutical Co Ltd
| Average Annual Return | 0.09% |
| Standard Deviation of Annual Returns | 10.11% |
| Max Drawdown | -55% |
| Market Capitalization | 3.8B CNY |
| Shares Outstanding | 1 182 210 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Huaren Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Huaren Pharmaceutical Co., Ltd. engages in development, manufacture, and sale of non polyvinyl chloride and non-PVC large capacity preparations. The company is headquartered in Qingdao, Shandong and currently employs 2,242 full-time employees. The company went IPO on 2010-08-25. The firm provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The firm distributes its products in domestic market, with Northeast China as its main market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Huaren Pharmaceutical Co Ltd
stock under the Base Case scenario is
3.56
CNY.
Compared to the current market price of 3.23 CNY,
Huaren Pharmaceutical Co Ltd
is
Undervalued by 9%.
You don't have any saved screeners yet
